Early initiation of rhythm control therapy was found to reduce cardiovascular outcomes in patients with newly diagnosed atrial fibrillation (AF) and cardiovascular conditions, according to the primary results of a clinical trial presented at the European Society of Cardiology Congress 2020, held virtually August 29 to September 1 and published in the New England Journal of Medicine.1,2 The results of the multi-center, prospective, randomized, open, blinded-outcome assessment Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST AFNET 4; ClinicalTrials.gov Identifier: NCT01288352) were presented by Paulus Kirchhof, MD, professor of cardiovascular medicine at the University Heart and Vascular Center at UKE Hamburg and first author on this study. An estimated 5% of patients with AF even when adequately managed are thought to experience serious cardiovascular events that include stroke, heart failure, acute coronary syndrome, and cardiovascular death. Antiarrhythmic drugs which, along with AF ablation are safe approaches for patients with AF and concomitant cardiovascular conditions were not found to be superior to rate control strategies in achieving rhythm control in patients with established AF in previous clinical trials. Continue reading →

Amid the COVID-19 pandemic, its easy to forget one of the largest health challenges we face remains the global obesity epidemic. World Health Organisation data shows obesity has nearly tripled in less than 50 years, with about 40 per cent of adults worldwide now overweight or obese. Continue reading →

Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast Continue reading →

There are no Food and Drug Administration (FDA)-approved treatments for COVID-19, the pandemic infection caused by a novel coronavirus. While several therapies are being tested in clinical trials, current standard of care involves providing patients with fluids and fever-reducing medications Continue reading →

The Global Nanomedicine Market report provides information by Key Players, Geography, End users, Applications, Competitor analysis, Sales, Revenue, Price, Gross Margin, Market Share, Import-Export, Trends and Forecast. Initially, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure Continue reading →

A Phase 2 clinical trial is getting underway at UC and nearly 20 other sites across the U.S. Continue reading →

Female patients who have a history of spontaneous coronary artery dissection (SCAD) do not necessarily face recurrent SCAD if they become pregnant, despite pregnancy being a known trigger of these rare but severe complications. The data, derived from a Mayo Clinic registry, were published online this week in JAMA Cardiology Continue reading →